Cellectar Biosciences, Inc. (CLRB)
Data as of , from SEC Form 4 filings.
See up to 3 months of CLRB. The 7-day demo opens the 1M and 3M ranges and puts CLRB on your watchlist.
Start 7-day demoLatest CLRB insider trades
Jarrod Longcor - OfficerOpen-market purchase$25K- Jarrod Longcor - OfficerOpen-market purchase$260
About Cellectar Biosciences, Inc. (CLRB)
The SEC lists Cellectar Biosciences, Inc. under CIK 0001279704, in pharmaceutical preparations. It is grouped with Health Care companies on this site. A registration statement was filed on 19 May 2026. No offering has priced.
CLRB Form 4 activity by transaction type, last 90 days
No Form 4 activity for CLRB in the last 90 days.
CLRB insider transactions (Form 4)
2116 Form 4 filings on record, the earliest from Jul 3, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Stefan Loren | Grant or award | Stock option (right to buy) | 15,000 | $0.00 | - | |
| Chad J. Kolean - Officer | Grant or award | Stock option (right to buy) | 92,000 | $0.00 | - | |
| Frederick W. Driscoll - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
| Asher Chanan-Khan - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
 James V. Caruso - Officer | Grant or award | Stock option (right to buy) | 250,000 | $0.00 | - | |
| Andrew Gu - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
| Jarrod Longcor - Officer | Grant or award | Stock option (right to buy) | 118,000 | $0.00 | - | |
 Douglas J. Swirsky - Director | Grant or award | Stock option (right to buy) | 37,500 | $0.00 | - | |
| John Neis - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
| Stefan Loren | Grant or award | Stock option (right to buy) | 15,000 | $0.00 | - | |
| Jarrod Longcor - Officer | Open-market purchase | Common Stock | 8,680 | $2.88 | $25K | |
| Jarrod Longcor - Officer | Open-market purchase | Warrants | 26,040 | $0.01 | $260 | |
| James V. Caruso - Officer | Open-market purchase | Common Stock | 8,680 | $2.88 | $25K | |
| James V. Caruso - Officer | Open-market purchase | Warrants | 26,040 | $0.01 | $260 | |
| John Neis - Director | Open-market sale | Common Stock | 198 | $3.70 footnote F1 | $732 | |
| ||||||
| James V. Caruso - Officer | Open-market purchase | Common Stock | 10,000 | $4.99 | $50K | |
| James V. Caruso - Officer | Open-market purchase | Warrants | 10,000 | $0.01 | $100 | |
| Jarrod Longcor - Officer | Open-market purchase | Common Stock | 10,000 | $4.99 | $50K | |
| Jarrod Longcor - Officer | Open-market purchase | Warrants | 10,000 | $0.01 | $100 | |
| Chad J. Kolean - Officer | Open-market purchase | Common Stock | 5,000 | $4.99 | $25K | |
| Chad J. Kolean - Officer | Open-market purchase | Warrants | 5,000 | $0.01 | $50 | |
CLRB insider trading FAQ
What is the latest insider trade for CLRB?
Cellectar Biosciences, Inc. (CLRB) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-11. The full record for CLRB runs to 16 Form 4 filings, the earliest from 2025-07-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CLRB stock?
No insider purchases of CLRB were filed in the last 90 days. 10 purchases are on record for this company.
How many insiders are selling CLRB stock?
No insider sales of CLRB were filed in the last 90 days. 1 sale is on record for this company.
Where can I see CLRB SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CLRB Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Stefan Loren view on EDGAR
- - Chad J. Kolean view on EDGAR
- - Frederick W. Driscoll view on EDGAR
- - Asher Chanan-Khan view on EDGAR
- - James V. Caruso view on EDGAR
- - Andrew Gu view on EDGAR
- - Jarrod Longcor view on EDGAR
- - Douglas J. Swirsky view on EDGAR
- - John Neis view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where CLRB's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CLRB with a 7-day demo
- CLRB on your watchlist
- Every CLRB Form 4 filing on record
- Up to 3 months of CLRB price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
